Structure Therapeutics (NASDAQ:GPCR) Posts Earnings Results, Misses Expectations By $0.10 EPS

Structure Therapeutics (NASDAQ:GPCR) announced its earnings results on Thursday. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.10), FiscalAI reports.

Structure Therapeutics Price Performance

Shares of NASDAQ:GPCR traded up $0.52 during trading hours on Friday, hitting $53.14. 329,459 shares of the company’s stock traded hands, compared to its average volume of 558,888. The firm has a market capitalization of $3.78 billion, a P/E ratio of -53.14 and a beta of -1.43. The business has a fifty day moving average price of $47.63 and a 200-day moving average price of $54.19. Structure Therapeutics has a 1 year low of $15.86 and a 1 year high of $94.90.

Institutional Investors Weigh In On Structure Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the business. Wellington Management Group LLP boosted its holdings in Structure Therapeutics by 25.2% during the 4th quarter. Wellington Management Group LLP now owns 7,121,984 shares of the company’s stock valued at $495,334,000 after acquiring an additional 1,432,797 shares during the period. Janus Henderson Group PLC increased its stake in Structure Therapeutics by 14.4% in the fourth quarter. Janus Henderson Group PLC now owns 5,090,148 shares of the company’s stock worth $354,006,000 after purchasing an additional 641,322 shares during the period. Morgan Stanley lifted its position in shares of Structure Therapeutics by 261.4% during the fourth quarter. Morgan Stanley now owns 2,087,834 shares of the company’s stock worth $145,209,000 after purchasing an additional 1,510,093 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its position in shares of Structure Therapeutics by 477.5% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,671,138 shares of the company’s stock worth $116,228,000 after purchasing an additional 1,381,745 shares during the last quarter. Finally, Ameriprise Financial Inc. lifted its position in shares of Structure Therapeutics by 7.2% during the second quarter. Ameriprise Financial Inc. now owns 1,588,198 shares of the company’s stock worth $32,939,000 after purchasing an additional 106,389 shares during the last quarter. 91.78% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on GPCR shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Structure Therapeutics in a research note on Friday, July 17th. Wall Street Zen raised Structure Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 1st. Canaccord Genuity Group set a $111.00 target price on Structure Therapeutics in a report on Friday. Citigroup reissued a “market outperform” rating on shares of Structure Therapeutics in a research report on Friday. Finally, Citizens Jmp lowered their price target on Structure Therapeutics from $113.00 to $110.00 and set a “market outperform” rating for the company in a research report on Friday. Three research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $110.91.

About Structure Therapeutics

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.